Kefodon 2 grams injection (Cefepime Sodium)

Adult administration

For sodium cefepime, for infections caused by gram-positive bacteria, 1 to 2g (potency) should be intravenously administered in 2 to 3 divided doses daily. For infections caused by gram-negative bacteria, 3 to 4g (potency) should be administered in 2 to 3 divided doses daily. For life-threatening infections and infections caused by moderately susceptible bacteria, the dose can be increased up to 6g (potency) daily. The dosage and interval for patients with renal impairment should be determined based on the extent of renal damage.

This drug should not be administered to patients with hypersensitivity to cephalosporin antibiotics. It is particularly advised against use in premature infants and neonates. Caution should be exercised when administering to pregnant women within the first three months of pregnancy, patients with impaired renal and liver function, patients with hemophilia or thrombocytopenia, and patients with gastrointestinal ulcers. Furthermore, patients who have difficulties swallowing or receive parenteral nutrition, elderly patients, and those in poor general condition may show symptoms of vitamin K deficiency, requiring careful observation. Mild hypersensitivity reactions such as transient headaches, dizziness, and nausea may occur when using this medication. Rarely, skin rashes, fever, and severe allergic reactions like anaphylaxis may occur, so if these symptoms arise, discontinuation of the drug and appropriate treatment should be initiated immediately. Increased liver function test values may occur rarely. Additionally, a temporary decrease in white blood cell count may occur, so it is essential to monitor blood status. Gastrointestinal side effects may rarely include severe colitis, and if frequent abdominal pain or diarrhea occurs, discontinuation should occur immediately. Nausea, vomiting, and loss of appetite may also appear. Respiratory symptoms may rarely include fever, cough, and respiratory distress, which could indicate interstitial pneumonia or PIE syndrome; discontinuation and appropriate treatment are required if these symptoms manifest. Phenomena such as oral candidiasis or dysbiosis may rarely appear. A tendency for bleeding due to vitamin K deficiency or symptoms of vitamin B complex deficiency may also occur, necessitating awareness. To prevent the development of resistant bacteria, it is advisable to administer the drug for only the minimum necessary duration based on susceptibility testing. It is also preferable to perform skin reaction tests prior to administration to check for allergic reactions, prepare for emergency treatment in case of shock, and ensure stable monitoring of the patient post-administration. Care should be taken when using this drug alongside aminoglycoside antibiotics, polymyxin B, colistin, and high-dose diuretics, as it may affect renal function. Blood coagulation status should be closely monitored when combined with high-dose oral anticoagulants like heparin. During breastfeeding, caution is advised as this drug may be excreted in small amounts in breast milk. Finally, care should be taken not to mix this drug with aminoglycoside antibiotics in the same syringe for injection.

Serious side effects

• Anaphylaxis
• severe colitis
• respiratory distress
• interstitial pneumonia
• PIE syndrome

Mild side effects

• Transient mild headache
• dizziness
• nausea
• skin rash
• fever
• vomiting
• loss of appetite
• membranous colitis
• abdominal pain
• frequent diarrhea

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature in the range of 1 to 30 degrees Celsius to effectively preserve the drug's efficacy and safety.

Appearance

A colorless and transparent vial containing a white to pale yellow powder.

Package unit

10 vials/box [(2 grams/vial) X 10]